TCM
ADAP

Tang Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Tang Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,743,619
Closed -$1.7M – 155
2024
Q2 		$1.7M Buy
1,743,619
+300,000
+21% +$329K 0.17% 83
2024
Q1 		$2.28M Sell
1,443,619
-2,943,619
-67% -$3.55M 0.24% 74
2023
Q4 		$3.48M Sell
4,387,238
-779,716
-15% -$440K 0.32% 73
2023
Q3 		$4.03M Buy
5,166,954
+279,716
+6% +$235K 0.57% 48
2023
Q2 		$4.52M Buy
+4,887,238
New +$5.83M 0.67% 42

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Tang Capital Management's ADAP Position: Q3 2024 in Review

Tang Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2024, closing a stake of 1,743,619 shares — an estimated $1.7M sold.

Tang Capital Management first reported a position in ADAP in Q2 2023 and held it in 5 quarters. The position peaked at $4.52M in Q2 2023. 81 funds tracked by Wall St. Rank hold ADAP as of Q3 2024.

  • Tang Capital Management reported no remaining Adaptimmune Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Tang Capital Management sold 1,743,619 Adaptimmune Therapeutics shares in Q3 2024, an estimated $1.7M.
  • Tang Capital Management first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 5 quarters.
  • Tang Capital Management's Adaptimmune Therapeutics position peaked at $4.52M in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2024.

Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.